Indian first-line ARV registered

SOUTH AFRICA: Indian first-line ARV registered

JOHANNESBURG, 26 Apr 2006 (PLUSNEWS) - Indian generic drug firm Cipla Medpro, this week announced one of its key antiretroviral (ARV) drugs had been registered in South Africa.

The drug Triomune - to be supplied through the local company, Enaleni Pharmaceuticals - was expected to help reduce the daily pill burden of HIV-positive patients from the current six or more tablets per day to only one pill in the morning and again at night.

"[This] is indeed a breakthrough and represents Cipla's commitment to making life-prolonging medicines accessible and affordable to the broader population," Trevor Edwards, CEO of Enaleni Pharmaceuticals said in a statement.

Triomune contains lamivudine, nevirapine and stavudine, which currently form part of first-line ARVs recommended by the South African Department of Health, and HIV Clinicians Society, as well as the World Health Organisation.

[ENDS]

[Back] [Home Page]

Click here to send any feedback, comments or questions you have about PlusNews Website or if you prefer you can send an Email to Webmaster

Copyright © IRIN 2006
The material contained on www.PlusNews.org comes to you via IRIN, a UN humanitarian news and information service, but may not necessarily reflect the views of the United Nations or its agencies.
All PlusNews material may be reposted or reprinted free-of-charge; refer to the IRIN copyright page for conditions of use. IRIN is a project of the UN Office for the Coordination of Humanitarian Affairs.